C. O'Bryan-Tear

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

S. Fosså, C. Parker, N. James, 2014, The Lancet. Oncology.

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

N. James, A. Cross, Chris Parker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.